US · Healthcare · Drug Manufacturers - Specialty & Generic
Analysts rate HUTCHMED DRC a strong buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $21.14.
CONFIDENT HUTCHMED delivered 23% oncology revenue growth H1 2026 on ELUNATE/SULANDA strength. Raised full-year guidance $330–450M. Advanced ATTC platform with 2 assets in Phase I, 3rd entering clinic. Sovleplenib NDA under priority review. H1 2026 China product sales robust (ELUNATE, SULANDA >40% growth). Ex-U.S. FRUZAQLA expansion accelerating. U.S. saw near-term Medicare headwinds but expected to stabilize. Takeda partnership driving global penetration. Analysts probed partnership status (immature, ongoing), HMPL-760 differentiation (reversible selectivity, large DLBCL unmet need), sovleplenib commercialization (HTA, NRDL strategy, 2027 launch). Management emphasized early-stage data sensitivity and strong clinical foundation; no concrete partnership terms disclosed. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| Schroder Investment Management Group | 0.85% |
| Allianz Asset Management AG | 0.39% |
| State Street Corp | 0.18% |
| AIA Group Ltd | 0.17% |
| M&G PLC | 0.14% |
| Amundi | 0.12% |
| Jane Street Group LLC | 0.11% |
| Renaissance Technologies Corp | 0.07% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • The US FDA granted Orphan Drug Designation to sovleplenib for autoimmune hemolytic anemia (AIHA). • This is sovleplenib’s second U | 2026-11-05 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • HUTCHMED announced that regulatory filings for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) have been accepted for review | 2026-11-02 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • The US FDA granted Orphan Drug Designation to sovleplenib for primary immune thrombocytopenia (ITP), a rare autoimmune disorder th | 2026-10-29 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • HUTCHMED will host an investor and analyst webcast on November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST. • The event w | 2026-10-27 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • SAFFRON Phase III tested ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) against doublet platinum-based chemotherapy in EGFR-mu | 2026-10-26 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • HUTCHMED announced the closing of its exclusive license agreement with GSK for HMPL-A830, a KRAS-EGFR antibody-targeted therapy co | 2026-10-21 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca submitted a US New Drug Application (NDA) for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in locally advanced | 2026-09-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • HUTCHMED initiated the Phase Ia portion of a global Phase I trial for HMPL-A830, a potential KRAS-EGFR antibody-targeted therapy c | 2026-09-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for HUTCHMED DRC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.